Introduction
============

ST2 receptor is a member of the Toll-like/interleukin-1 (IL-1) receptor family with research works in animal models showing that cytokine IL-33 interacts with ST2 receptors in cardiac myocytes, thereby comprising a cardioprotective stress-responsive signaling system.[@b1-vhrm-13-311] ST2 is induced in conditions of myocardial overload, such as myocardial infarction, when the remaining viable myocardium must bear more stress.[@b1-vhrm-13-311] Soluble ST2 has been found to be increased in the serum of patients 1 day after myocardial infarction, and its serum levels predict outcome in patients with heart failure (HF).[@b2-vhrm-13-311] Several other studies have shown that soluble ST2 levels correlate with severity of HF, left ventricular ejection fraction (LVEF), creatinine clearance, B-type natriuretic peptide and C-reactive protein, and are predictors of mortality.[@b3-vhrm-13-311],[@b4-vhrm-13-311] In addition, soluble ST2 has also been found to be a useful biomarker in differentiating the various spectra of hypertensive heart disease.[@b5-vhrm-13-311] Most of these findings, however, were limited to not only ischemic heart disease but also left-sided HF. We therefore decided to study the relationship between soluble ST2 and some markers of right ventricular (RV) function in a cohort of hypertensive HF subjects of a population where hypertension is the commonest cause of HF.[@b6-vhrm-13-311],[@b7-vhrm-13-311]

Patients and methods
====================

Subjects
--------

This prospective cohort study was approved by the ethical clearance committee of the University of Abuja Teaching Hospital and is in compliance with the Declaration of Helsinki, and, wherever possible, it also adheres to the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) guidelines for an observational study of this kind. The minimum age for participation in the study was 18 years, but there was no upper age limit. Of the 81 patients enrolled for the study, four (4.9%) of the total enrolment was excluded because patients were diabetic, had regional wall motion abnormality on transthoracic echocardiography, had serum creatinine levels \>170 μmol/L or had previous acute myocardial infarction. Therefore, 77 subjects with hypertensive HF were studied. Hypertension was defined according to the Joint National Committee VII guidelines.[@b8-vhrm-13-311] The subjects also had clinical features of long-standing hypertension, which included thickened arterial wall, locomotor brachialis and at least Grade 2 hypertensive retinopathy. HF was diagnosed according to the guidelines of the European Society of Cardiology.[@b9-vhrm-13-311] The functional status of the HF subjects was according to the guidelines of New York Heart Association Functional Classification.[@b10-vhrm-13-311] All subjects gave written informed consent to participate in the study.

Questionnaire
-------------

All the subjects completed a standard questionnaire. Owing to the multiplicity of languages in Nigeria, the questionnaire was not translated into any of the local languages. The majority of the subjects were reasonably proficient in English language. Where there was a need for interpretation, both medical and paramedical staff of the Cardiology Unit of the Department of Medicine of University of Abuja Teaching Hospital assisted. The questionnaire requested specific answers regarding date of birth, gender, occupation, background diagnosis of hypertension, background diagnosis of diabetes mellitus, history of angina pains, history of alcohol consumption and history of smoking habits.

Anthropometric measurements and conventional blood pressure (BP) measurements
-----------------------------------------------------------------------------

The height and weight of the subjects were measured in the clinic by nursing staff with the participants standing and wearing indoor clothes with no shoes. Body mass index was calculated as weight in kilograms divided by the square of height in meters. Body surface area in square meter (m^2^) was calculated as (0.0001)×(71.84)×(weight in kg)^0.425^×(height in cm)^0.725^.

BP measurements were obtained according to the standard guidelines with a mercury sphygmomanometer (Accoson, London, UK). Systolic BP and diastolic BP were measured by cardiologists at Korotkoff sounds I and V, respectively. BP was measured at the right arm three times after a 5-minute rest with the patient in the sitting position, and the average of the three measurements was obtained. Pulse pressure was calculated as systolic BP minus diastolic BP, while mean arterial pressure was calculated as one-third of diastolic BP plus pulse pressure.

Blood measurements
------------------

Blood samples were collected for fasting blood sugar, fasting lipid profile, electrolyte, urea and creatinine and full blood count and for NT-proBNP and ST2 assay. The blood was put into EDTA tubes, and the samples were immediately centrifuged and plasma separated and then stored at −80°C until assayed. Samples were transported in dry ice and shipped to the Hatter Institute of Cardiovascular Research in Africa; the assay was carried. Details of NT-proBNP and ST2 assay have been described in our previous publication.[@b11-vhrm-13-311]

Transthoracic echocardiography
------------------------------

Echocardiography was performed using a commercially available ultrasound system (IVIS-60). Details of echocardiography have been previously reported in a similar paper by authors.[@b12-vhrm-13-311]

Data analysis
-------------

SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Continuous variables were expressed as mean ± SD. Comparison of demographic, clinical, laboratory and echocardiographic parameters among the three groups was performed by analysis of variance. Correlation coefficients were calculated by linear regression analysis with serum NT-proBNP and soluble ST2 log transformed to establish normality, and correlations between tricuspid annular plane systolic excursion (TAPSE) and continuous demographic, clinical, laboratory and echocardiographic parameters were evaluated by Spearman regression.

Results
=======

Clinical profile of the subjects
--------------------------------

[Table 1](#t1-vhrm-13-311){ref-type="table"} shows the clinical profile of the subjects studied. The subjects were middle aged with mean age of 53.8±13.2years. There was no significant difference between the ages of the male and female subjects; nor was there a difference in the body mass index between the male and female subjects. Men smoked more than women (18.6% versus 2.5%, *p*-value \<0.0001) and had worse renal function with the estimated glomerular filtration rate of 111.6±41.4 mL/min versus 78.3±17.0 mL/min in women (*p*-value \<0.0001). The women presented more often with palpitations (57.7% versus 48.9%, *p*-value =0.02). Serum ST2 and NT-proBNP levels were similar in men and women.

Echocardiographic profile of the subjects
-----------------------------------------

[Table 2](#t2-vhrm-13-311){ref-type="table"} shows the echocardiographic profile of the subjects. The male subjects had significantly more hypertrophy involving the interventricular septal wall compared to the female subjects. They also had a more dilated left ventricle (LV), especially in diastole, compared to the female subjects. There was no gender difference in the LV mass indexed for height.[@b2-vhrm-13-311],[@b7-vhrm-13-311] Using TAPSE, 33 (42.9%) of the subjects had impaired RV systolic function.

Relationship between TAPSE and echocardiographic and laboratory parameters
--------------------------------------------------------------------------

[Table 3](#t3-vhrm-13-311){ref-type="table"} shows the relationship between RV systolic function as assessed by TAPSE and various echocardiographic and laboratory parameters. Left atrial diameter, areas of both atria, LV end-diastolic and end-systolic diameters, LV mass index, right ventricular systolic pressure (RVSP), LVEF and transmitral *E*/*A* ratio correlated significantly with TAPSE. There was no significant correlation between TAPSE and cardiac biomarkers.

Univariate association between log-transformed ST2 and echocardiographic right-sided parameters
-----------------------------------------------------------------------------------------------

[Table 4](#t4-vhrm-13-311){ref-type="table"} shows that soluble ST2 correlates significantly with RVSP, right ventricular diameter in diastole (RVDD) and right atrial area (RAA), while NT-proBNP only correlates significantly with RVSP and RAA.

Discussion
==========

Our study has shown a correlation between soluble ST2 and RVSP, RVDD and RAA, supporting a previous report in a cohort of HF secondary to ischemic heart disease and idiopathic dilated cardiomyopathy.[@b13-vhrm-13-311] Therefore, the relationship between ST2 and RVSP is not only restricted to both ischemic heart disease and idiopathic dilated cardiomyopathy but extends to hypertensive HF. We did not however find any correlation between soluble ST2 and tricuspid annular plane excursion. This finding has to be further verified in a larger cohort. Although NT-proBNP correlated well with RVSP and RAA, there was poor correlation with RVDD, which may suggest that soluble ST2 is a better circulating biomarker than the more traditional NT-proBNP in assessing hypertensive HF.

On linear regression analysis, factors that were associated with abnormal RV function included dilated left atrium and LV, increased LV mass, reduced LV systolic function, restrictive filling pattern and RVSP. LV dilation has been previously shown to have an impact on RV function as measured by TAPSE.[@b14-vhrm-13-311] It has been previously shown that a reduced LVEF impacts on TAPSE even in the setting of preserved RV ejection fraction.[@b14-vhrm-13-311],[@b15-vhrm-13-311] The effect of LVEF on TAPSE has been attributed to ventricular interdependence.[@b16-vhrm-13-311]

The finding in our study of an inverse relationship between RV systolic function and RVSP is in accordance with most previous studies.[@b17-vhrm-13-311] This relationship has been reported in patients with dilated cardiomyopathy and ischemic heart diseases, supporting the fact that the major determinant of RV systolic function in left-sided HF is after load mismatch due to increase in pulmonary artery resistance.[@b17-vhrm-13-311] TAPSE correlated with markers of diastolic dysfunction and RVSP in our study but not with RV end-diastolic diameter as previously reported.[@b18-vhrm-13-311]

We found RV systolic dysfunction (measured by TAPSE) in 33 of the 77 subjects studied. The high prevalence of RV systolic dysfunction in our hypertensive HF cohort might partly explain the poor prognosis that is found in our subjects,[@b19-vhrm-13-311] as RV systolic dysfunction is a poor prognostic factor in HF.[@b16-vhrm-13-311],[@b17-vhrm-13-311] There is a need therefore to pay more attention to RV function, which has often been neglected in hypertensive HF subjects. The impairment of RV function in left-sided HF has been linked to ventricular interdependence,[@b18-vhrm-13-311] which is always present in HF, being most apparent with changes in loading conditions such as those seen with volume loading.[@b15-vhrm-13-311]

Limitation
----------

Since our study is limited by the number of subjects, the relationship between plasma ST2 and echocardiographic variables seen in this study should be viewed as hypothesis generating for studies in larger patient cohorts. In addition, RV function was only assessed by TAPSE and not by other parameters such as TAPSE/pulmonary arterial systolic pressure (PAPS) and fractional area change (FAC). In addition, since the diagnosis of ischemic heart was made clinically using history, troponin I levels and electrocardiography with no myocardial perfusion imaging and coronary angiography performed, it is possible that subtle coronary artery disease might have been missed, which is a confounding factor as ischemic heart disease increases the concentration of soluble ST2.[@b2-vhrm-13-311],[@b3-vhrm-13-311] However, the careful and extensive phenotyping of our study population with respect to clinical, echocardiographic and biochemical parameters must have reduced the effect of these limitations and is, therefore, a strong point in this study.

Conclusion
==========

A higher concentration of soluble ST2 correlates with higher RVSP in a cohort of hypertensive HF. Therefore, the association of ST2 with RVSP is not only limited to HF due to ischemic heart disease and idiopathic dilated cardiomyopathy but also HF secondary to hypertensive heart disease.
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###### 

Clinical profile of subjects

  Parameters                        All (N=77)    Male (n=54)   Female (n=23)   *p*-value
  --------------------------------- ------------- ------------- --------------- -----------
  Age, years                        53.8±13.2     53.8±15.8     51.7±13.6       0.56
  Smoking habits, n (%)             24 (13.1)     22 (18.6)     2 (2.5)         \<0.001
  Body mass index, kg/m^2^          24.30±7.0     24.2±7.6      24.5±5.9        0.86
  Palpitations, n (%)               40 (51.9)     24 (44.4)     16 (69.6)       0.002
  Peripheral edema, n (%)           49 (63.2)     35 (64.8)     14 (60.8)       NS
  NYHA class, n (%)                                                             
   II                               14 (18.2)     10 (18.5)     4 (17.5)        
   III                              49 (63.6)     35 (64.8)     14 (60.8)       
   IV                               14 (18.2)     9 (16.7)      5 (21.7)        
  SBP, mmHg                         149.1±23.8    149.9±23.8    147.7±23.9      0.55
  DBP, mmHg                         98.1±13.9     98.2±13.9     97.9±13.9       0.92
  PP, mmHg                          55.8±16.2     56.4±16.8     54.7±15.0       0.52
  MAP, mmHg                         101.3±16.4    101.2±17.2    101.5±15.0      0.89
  FBS, mmol/L                       5.3±2.2       5.2±2.0       5.4±2.4         0.58
  TC, mmol/L                        4.2±1.2       4.1±0.2       4.3±1.2         0.22
  LDLC, mmol/L                      2.7±0.9       2.6±1.0       2.8±1.0         0.14
  HDLC, mmol/L                      1.1±0.4       1.1±0.4       1.1±0.3         0.63
  Estimated GFR, mL/min/1.73 m^2^   101.5±38.8    111.6±41.4    78.3±17.0       \<0.0001
  NT-proBNP, pg/mL                  501.7±199.8   513.0±208.5   478.7±184.7     0.58
  Serum ST2, ng/mL                  112.9±78.7    100.1±60.4    134.4±98.3      0.26

**Note:** Data presented as mean ± SD unless otherwise stated.

**Abbreviations:** NS, not significant; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; FBS, fasting blood sugar; TC, total cholesterol; LDLC, low-density lipoprotein cholesterol; HDLC, high-density lipoprotein cholesterol; GFR, glomerular filtration rate.

###### 

Echocardiographic profile of subjects

  Parameters            All (N=77)   Male (n=54)   Female (n=22)   *p*-value
  --------------------- ------------ ------------- --------------- -----------
  RVDD, cm              3.4±0.6      3.5±0.6       3.2±0.5         0.22
  Left atrium, cm       4.6±0.9      4.6±0.9       4.5±0.8         0.17
  IVSD, cm              1.1±0.3      1.1±0.2       1.0±0.3         0.03
  PWD, cm               1.1±0.2      1.2±0.2       1.1±0.2         0.07
  EDD, cm               5.8±1.1      5.9±1.1       5.5±1.1         0.04
  ESD, cm               4.7±1.3      4.9±1.2       4.5±1.3         0.07
  LAA, cm^2^            24.5±7.0     24.5±6.7      24.4±7.5        0.95
  RAA, cm^2^            22.3±8.1     22.6±8.0      21.7±8.5        0.50
  LVM/HT^2.7^           108.3±46.3   117.5±35.4    112.5±42.3      0.65
  LVEF, %               35.2±17.5    34.4±16.8     36.6±18.7       0.58
  ME, m/s               0.78±0.3     0.76±0.30     0.81±0.30       0.43
  MA, m/s               0.49±0.2     0.49±0.2      0.49±0.1        0.25
  ME/MA                 2.2±1.3      2.0±1.2       2.2±1.4         0.96
  DT, ms                143.2±80.6   143.7±85.1    142.2±72.2      0.22
  TAPSE, mm             16.2±5.1     16.6±5.4      15.5±4.5        0.16
  TAPSE\<15 mm, n (%)   33 (42.9)    54 (40.7)     10 (41.7)       0.18
  RVSP, mmHg            31.4±10.5    31.4±10.4     31.3±10.5       0.97

**Abbreviations:** RVDD, right ventricular diameter in diastole; IVSD, interventricular septal diameter in diastole; PWD, posterior wall diameter in diastole; EDD, end-diastolic diameter; ESD, end-systolic diameter; LAA, left atrial area; RAA, right atrial area; LVM, left ventricular mass; HT, height; LVEF, left ventricular ejection fraction; ME, early mitral inflow; MA, late mitral inflow; DT, deceleration time; TAPSE, tricuspid annular plane systolic excursion; RVSP, right ventricular systolic pressure.

###### 

Univariate analysis with RV systolic function using TAPSE

  Parameters             Pearson correlation   *p*-value
  ---------------------- --------------------- -----------
  Left atrial diameter   −0.54                 \<0.0001
  EDD                    −0.47                 \<0.0001
  ESD                    −0.55                 \<0.0001
  LVM/HT^2.7^            −0.34                 \<0.0001
  LVEF                   0.60                  \<0.0001
  ME/MA                  −0.39                 \<0.0001
  Left atrial area       −0.24                 0.02
  RAA                    −0.44                 \<0.0001
  RVSP                   −0.74                 \<0.0001
  RVDD                   −0.035                0.77
  Soluble ST2            0.04                  0.68
  NT-proBNP              0.000                 0.99

**Abbreviations:** RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion; EDD, end-diastolic diameter; ESD, end-systolic diameter; HT, height; LVM, left ventricular mass; LVEF, left ventricular ejection fraction; ME, early mitral inflow; MA, late mitral inflow; RAA, right atrial area; RVSP, right ventricular systolic pressure; RVDD, right ventricular diameter in diastole.

###### 

Univariate and multivariate associations between log-transformed ST2 and echocardiography right-sided parameters

  Univariate association   Multivariate association                                                                                       
  ------------------------ -------------------------------------------------- ---------------------------------------------------- ------ ---------
  RVSP                     0.75[\*](#tfn6-vhrm-13-311){ref-type="table-fn"}   0.54[\*\*](#tfn7-vhrm-13-311){ref-type="table-fn"}   0.46   \<0.001
  RAA                      0.46[\*](#tfn6-vhrm-13-311){ref-type="table-fn"}   0.20[\*\*](#tfn7-vhrm-13-311){ref-type="table-fn"}   034    0.003
  RVDD                     0.28[\*](#tfn6-vhrm-13-311){ref-type="table-fn"}   0.09                                                 --     --
  TAPSE                    −0.15                                              −0.13                                                --     --

**Notes:** R1, coefficient of correlation between soluble ST2 and variables; R2, coefficient of correlation between NT-proBNP and variables.

*p*\<0.05 versus soluble ST2.

*p*\<0.05 versus NT-proBNP.

**Abbreviations:** RVSP, right ventricular systolic pressure; RAA, right atrial area; RVDD, right ventricular diameter in diastole; TAPSE, tricuspid annular plane systolic excursion.
